000134858 001__ 134858
000134858 005__ 20240229105044.0
000134858 0247_ $$2doi$$a10.1016/j.ctcp.2018.03.004
000134858 0247_ $$2pmid$$apmid:29705471
000134858 0247_ $$2ISSN$$a1744-3881
000134858 0247_ $$2ISSN$$a1873-6947
000134858 0247_ $$2altmetric$$aaltmetric:70321815
000134858 037__ $$aDKFZ-2018-00648
000134858 041__ $$aeng
000134858 082__ $$a610
000134858 1001_ $$aMajdinasab, Nastaran$$b0
000134858 245__ $$aAcute responses of cytokines and adipokines to aerobic exercise in relapsing vs. remitting women with multiple sclerosis.
000134858 260__ $$aEdinburgh [u.a.]$$bElsevier44913$$c2018
000134858 3367_ $$2DRIVER$$aarticle
000134858 3367_ $$2DataCite$$aOutput Types/Journal article
000134858 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1529307951_27072
000134858 3367_ $$2BibTeX$$aARTICLE
000134858 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000134858 3367_ $$00$$2EndNote$$aJournal Article
000134858 520__ $$aTo examine the acute effect of exercise on cytokines and adipokines during relapse and the remitting phase of multiple sclerosis (MS).Thirty women with MS in the relapsing or remitting phase were matched with fifteen healthy controls. Participants performed a single-bout of aerobic exercise at 60-70% maximal heart rate. Furthermore, five women in the relapsing phase were enrolled (control relapse) and did not receive any intervention. Blood samples were taken before, immediately after, 1-h and 6-h after the exercise.Levels of IL-10 and TNF-α in response to exercise were similar in healthy and MS remitting subjects. Compared to baseline, TNF-α levels in relapsing subjects were significantly decreased immediately after exercise. Immediately following exercise, leptin levels significantly decreased in relapsing subjects. Adiponectin and IL-6 showed no significant difference between groups.After relapse, exercise does not induce inflammatory cytokine response and temporarily improves both cytokine and adipokine balance.
000134858 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000134858 588__ $$aDataset connected to CrossRef, PubMed,
000134858 7001_ $$aMotl, Robert W$$b1
000134858 7001_ $$aMokhtarzade, Motahare$$b2
000134858 7001_ $$0P:(DE-He78)d05b24af674d8ef2c455634434b67770$$aZimmer, Philipp$$b3$$udkfz
000134858 7001_ $$aRanjbar, Rouholah$$b4
000134858 7001_ $$aKeytsman, Charly$$b5
000134858 7001_ $$aCullen, Tom$$b6
000134858 7001_ $$aNegaresh, Raoof$$b7
000134858 7001_ $$aBaker, Julien S$$b8
000134858 773__ $$0PERI:(DE-600)2181895-2$$a10.1016/j.ctcp.2018.03.004$$gVol. 31, p. 295 - 301$$p295 - 301$$tComplementary therapies in clinical practice$$v31$$x1744-3881$$y2018
000134858 909CO $$ooai:inrepo02.dkfz.de:134858$$pVDB
000134858 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d05b24af674d8ef2c455634434b67770$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000134858 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000134858 9141_ $$y2018
000134858 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCOMPLEMENT THER CLIN : 2015
000134858 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000134858 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000134858 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000134858 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000134858 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000134858 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000134858 9201_ $$0I:(DE-He78)G210-20160331$$kG210$$lBewegung, Präventionsforschung und Krebs$$x0
000134858 980__ $$ajournal
000134858 980__ $$aVDB
000134858 980__ $$aI:(DE-He78)G210-20160331
000134858 980__ $$aUNRESTRICTED